BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 7448772)

  • 21. Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity.
    Bousquet PF; Braña MF; Conlon D; Fitzgerald KM; Perron D; Cocchiaro C; Miller R; Moran M; George J; Qian XD
    Cancer Res; 1995 Mar; 55(5):1176-80. PubMed ID: 7867004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
    Dexter DL; Hesson DP; Ardecky RJ; Rao GV; Tippett DL; Dusak BA; Paull KD; Plowman J; DeLarco BM; Narayanan VL
    Cancer Res; 1985 Nov; 45(11 Pt 1):5563-8. PubMed ID: 4053030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin.
    Kjønniksen I; Breistøl K; Fodstad O
    Cancer Res; 1992 Mar; 52(5):1347-51. PubMed ID: 1737396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
    Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
    Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.
    Pratesi G; De Cesare M; Caserini C; Perego P; Dal Bo L; Polizzi D; Supino R; Bigioni M; Manzini S; Iafrate E; Salvatore C; Casazza A; Arcamone F; Zunino F
    Clin Cancer Res; 1998 Nov; 4(11):2833-9. PubMed ID: 9829750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapy for mouse tumors and human tumor xenografts with the antitumor antibiotic AT-125.
    Houchens DP; Ovejera AA; Sheridan MA; Johnson RK; Bogden AE; Neil GL
    Cancer Treat Rep; 1979 Mar; 63(3):473-6. PubMed ID: 427827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
    Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
    Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice.
    Taghian A; Budach W; Zietman A; Freeman J; Gioioso D; Ruka W; Suit HD
    Cancer Res; 1993 Oct; 53(20):5012-7. PubMed ID: 8402692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
    Trail PA; Willner D; Bianchi AB; Henderson AJ; TrailSmith MD; Girit E; Lasch S; Hellström I; Hellström KE
    Clin Cancer Res; 1999 Nov; 5(11):3632-8. PubMed ID: 10589780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of human tumors established in nude mice after continuous infusion of thymidine.
    Lee SS; Giovanella BC; Stehlin JS; Brunn JC
    Cancer Res; 1979 Aug; 39(8):2928-33. PubMed ID: 455279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts.
    Feng N; Jin H; Wang M; Du C; Wright JA; Young AH
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):247-55. PubMed ID: 12655444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth patterns and metastatic behavior of human tumors growing in athymic mice.
    Kyriazis AP; DiPersio L; Michael GJ; Pesce AJ; Stinnett JD
    Cancer Res; 1978 Oct; 38(10):3186-90. PubMed ID: 688209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
    Vadgama JV; Wu Y; Shen D; Hsia S; Block J
    Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adriamycin response of two human tumor xenografts using a double-radiolabel organ culture method.
    Sullivan JL; Sullivan LG
    Neoplasma; 1989; 36(6):685-90. PubMed ID: 2615871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Growth of human tumor transplanted into nude mice with various genetic backgrounds].
    Kubota T; Asanuma F; Kurihara H; Konno H; Koh J; Inada T; Kubochi K; Watanabe M; Suzuki K; Ishibiki K
    Gan To Kagaku Ryoho; 1984 Jan; 11(1):104-10. PubMed ID: 6538080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro growth and drug sensitivity of tumor colony-forming units from human tumor xenografts.
    Taetle R; Koessler AK; Howel SB
    Cancer Res; 1981 May; 41(5):1856-60. PubMed ID: 7214353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.